Dex 21 phosphate disodium salt

Totally 15 NOD/SCID mice were injected via the tail vein with 5×10⁶ MM1R-Luc-GFP cells (Gift from Dr. Constantine S Mitsiades, at DFCI), and one week after injection, the mice were randomized to seperate to control and treated groups and treated by intraperitoneal injection once a week with vehicle, RNA-LANCErII (BioScience) to control mice, or 1:1 as-miR-221 and as-miR-222 (as-miR-221-222 mix) (100 pmol total, pre-mixed in RNA-LANCErII) to treatment group mice. All mice were intraperitoneally injected with 9 mg/kg Dex-21-phosphate disodium salt (Sigma-Aldrich) on days 2~5, 9~12, 17~20, and 25~28. Tumor development was monitored by whole-body imaging using a Xenogen system. Mice were evaluated every week after initiation of treatment, and survival was evaluated from the day of tumor injection until death.

5 ×10⁶ MM1S cells stably transduced with V-miR-221-222-GFP or V-GFP and MM1R cells, stably transduced with V-as-miR-221-222-GFP or V-GFP, were injected via the tail vein into CB17.Cg-PrkdcscidLystbg-J/Crl mice (Code 250, Charles River) to establish a disseminated human MM xenograft model as previously described (12 (link)). Survival was evaluated from the first day of tumor injection until death. All mice were intraperitoneally injected with 9mg/kg Dex-21-phosphate disodium salt (Sigma-Aldrich) on days 1~4, 9~12, and 17~20. Mice were observed daily and sacrificed when hind limb paralysis was detected. Hind limb paralysis and tumor burden were used as an endpoint. To assess in vivo cell proliferation, apoptosis, and expression of miR-221-222 target genes, GFP-positive tumor samples were excised for immunohistochemical analysis, as in previous studies (12 (link)). All experiments involving animals were pre-approved by the DFCI Institutional Animal Care and Use Committee.